Tibolone in postmenopausal women with systemic lupus erythematosus: A pilot study

Maturitas

Volumn 62, Issue 3, 2009, Pages 311-316

  Vieira, Carolina Sales ^a   Pereira, Fábio Vasconcelos ^a   de Sá, Marcos Felipe Silva ^a   Júnior, Paulo Louzada ^a   Martins, Wellington Paula ^a   Ferriani, Rui Alberto ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Hormone replacement therapy; Postmenopause; SLEDAI; Systemic lupus erythematosus; Tibolone; Vasomotor symptoms

Indexed keywords

GLYCOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TIBOLONE;

ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; POSTMENOPAUSE; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS;

CHOLESTEROL, HDL; DOUBLE-BLIND METHOD; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; NORPREGNENES; PILOT PROJECTS; POSTMENOPAUSE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 62849120699     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2008.12.021     Document Type: Article

References (43)

1. Costenbader K.H., Feskanich D., Stampfer M.J., and Karlson E.W. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum 56 (2007) 1251-1262
2. Buyon J.P., Petri M.A., Kim M.Y., et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 142 (2005) 953-962
3. Urowitz M.B., Ibanez D., Jerome D., and Gladman D.D. The effect of menopause on disease activity in systemic lupus erythematosus. J Rheumatol 33 (2006) 2192-2198
4. Pines A., Sturdee D.W., Birkhauser M.H., Schneider H.P., Gambacciani M., and Panay N. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 10 (2007) 181-194
5. ACR. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum 50 (2004) 3418-3426
6. Kenemans P., and Speroff L. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 51 (2005) 21-28
7. Sadarangani A., Salgado A.M., Kato S., et al. In vivo and in vitro estrogenic and progestagenic actions of Tibolone. Biol Res 38 (2005) 245-258
8. Nathorst-Boos J., and Hammar M. Effect on sexual life-a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas 26 (1997) 15-20
9. Castelo-Branco C., Vicente J.J., Figueras F., et al. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 34 (2000) 161-168
10. Cutolo M., Sulli A., Capellino S., et al. Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus 13 (2004) 635-638
11. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., and Chang C.H. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35 (1992) 630-640
12. Petri M., Genovese M., Engle E., and Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 34 (1991) 937-944
13. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
14. Kupperman H.S., Blatt M.H., Wiesbader H., and Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol Metab 13 (1953) 688-703
15. Cooper G.S., Dooley M.A., Treadwell E.L., St Clair E.W., and Gilkeson G.S. Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case-control study. Arthritis Rheum 46 (2002) 1830-1839
16. Ramsey-Goldman R., Dunn J.E., Huang C.F., et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 42 (1999) 882-890
17. Sanchez-Guerrero J., Gonzalez-Perez M., Durand-Carbajal M., et al. Menopause hormonal therapy in women with systemic lupus erythematosus. Arthritis Rheum 56 (2007) 3070-3079
18. Kreidstein S., Urowitz M.B., Gladman D.D., and Gough J. Hormone replacement therapy in systemic lupus erythematosus. J Rheumatol 24 (1997) 2149-2152
19. Mok C.C., Lau C.S., Ho C.T., Lee K.W., Mok M.Y., and Wong R.W. Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus. Scand J Rheumatol 27 (1998) 342-346
20. NAMS. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause 14 (2007) 168-182
21. Brunner H.I., Feldman B.M., Bombardier C., and Silverman E.D. Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum 42 (1999) 1354-1360
22. Petri M., Buyon J., and Kim M. Classification and definition of major flares in SLE clinical trials. Lupus 8 (1999) 685-691
23. Mok C.C., To C.H., Mak A., and Ma K.M. Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study. Arthritis Rheum 52 (2005) 3997-4002
24. Petri M., Kim M.Y., Kalunian K.C., et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353 (2005) 2550-2558
25. Cummings S.R., Ettinger B., Delmas P.D., et al. The effects of tibolone in older postmenopausal women. N Engl J Med 359 (2008) 697-708
26. Baracat E.C., Barbosa I.C., Giordano M.G., et al. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability. Climacteric 5 (2002) 60-69
27. Swanson S.G., Drosman S., Helmond F.A., and Stathopoulos V.M. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study. Menopause 13 (2006) 917-925
28. Wender M.C., Edelweiss M.I., Campos L.S., de Castro J.A., and Spritzer P.M. Endometrial assessment in women using tibolone or placebo: 1-year randomized trial and 2-year observational study. Menopause 11 (2004) 423-429
29. Conner P., Christow A., Kersemaekers W., et al. A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolon and continuous combined estrogen-progestogen treatment. Climacteric 7 (2004) 50-58
30. Valdivia I., Campodonico I., Tapia A., Capetillo M., Espinoza A., and Lavin P. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril 81 (2004) 617-623
31. Beral V., Bull D., and Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365 (2005) 1543-1551
32. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
33. Verheul H.A., Schot L.P., Deckers G.H., and Schuurs A.H. Effects of tibolone, lynestrenol, ethylestrenol, and desogestrel on autoimmune disorders in NZB/W mice. Clin Immunol Immunopathol 38 (1986) 198-208
34. Schindler A.E., Campagnoli C., Druckmann R., et al. Classification and pharmacology of progestins. Maturitas 46 Suppl 1 (2003) S7-S16
35. Sarabi Z.S., Chang E., Bobba R., et al. Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. Arthritis Rheum 53 (2005) 609-612
36. Skouby S.O., Sidelmann J.J., Nilas L., and Jespersen J. A comparative study of the effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on blood coagulability. Hum Reprod 22 (2007) 1186-1191
37. Eilertsen A.L., Liestol S., Mowinckel M.C., Hemker H.C., and Sandset P.M. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system. Thromb Haemost 97 (2007) 938-943
38. Koh K.K., Ahn J.Y., Jin D.K., et al. Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study. Arterioscler Thromb Vasc Biol 23 (2003) 1889-1894
39. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107 (2003) 363-369
40. Barnes E.V., Narain S., Naranjo A., et al. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 14 (2005) 576-582
41. Lakoski S.G., and Herrington D.M. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article. Climacteric 8 (2005) 317-326
42. Bermudez E.A., Rifai N., Buring J., Manson J.E., and Ridker P.M. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 22 (2002) 1668-1673
43. Tan E.M., Cohen A.S., Fries J.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25 11 (1982) 1271-1277